Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, March 21, 2025

Creatinine-Cystatin C Ratio May Be a Predictive Biomarker for Sarcopenia in Midlife Women

 

How is your competent? doctor ensuring that you don't get muscle loss/sarcopenia? DOING NOTHING? So, you DON'T have a functioning doctor, do you?

Sarcopenia has been known as a problem for a long time. And your incompetent doctor has done nothing in the past 9+ years I bet!

  • sarcopenia (19 posts to March 2016)
  • Creatinine-Cystatin C Ratio May Be a Predictive Biomarker for Sarcopenia in Midlife Women

    Having a low creatinine-cystatin C ratio (CCR) at baseline was associated with lower fat-free muscle volumes and poorer gait speeds 6.6 years later in midlife women, according to a study published in the journal Menopause.

    “The potential of CCR as a predictive biomarker for adverse events related to sarcopenia in midlife women merits further investigation,” wrote Eu-Leong Yong, National University of Singapore, Singapore, and colleagues.

    To date, muscle mass is most accurately measured with 3D-imaging technologies, such as MRI. However, these tests are expensive and rely on highly trained staff to compute highly technical calculations. Other types of available diagnostics, such as measures of handgrip strength and physical performance, are time-consuming and require specially trained personnel. There is a need for simpler and more practical methods that can simultaneously assess total skeletal muscle mass and function.

    For the current study, the researcher examined 891 participants (baseline mean age, 56.2 ± 6.0 years) from the Integrated Women's Health Programme (IWHP) cohort who attended both baseline and follow-up visits, and underwent objectively measured muscle strength and physical performance assessments and MRI. Creatinine to cystatin C ratio was calculated as (creatinine [mg/dL] / cystatin C [mg/L]) and low CCR were those in the lowest tertile (CCR <8.16). 

    Baseline low CCR was associated with lower MRI-measured muscle volumes and poorer physical function 6.6 years later.

    Compared with the high CCR group, mean fat-free thigh muscle volume of the low CCR group was 0.350 L lower after adjustment for covariates. Similarly, the low CCR group was associated with 0.029 m/s slower mean usual gait and 0.049 m/s slower mean narrow gait speeds.

    CCR was not associated with handgrip strength and repeated chair stands and one-leg stand tests.

    “Because both muscle volume and poorer gait speed are constituents of current diagnostic criteria of sarcopenia, CCR may be a tool to help identify midlife women at risk of developing early sarcopenia and associated probability of adverse health outcomes,” commented Stephanie Faubion, MD, Mayo Clinic, Rochester, Minnesota, and the Medical Director of The Menopause Society. “Regardless of baseline risk, all midlife women should strive to mitigate loss of muscle mass with regular resistance training and adequate dietary protein intake to help prevent frailty as they age.”

    Reference: https://journals.lww.com/menopausejournal/abstract/9900/low_creatinine_to_cystatin_c_ratio_is_associated.440.aspx

    SOURCE: The Menopause Society

    No comments:

    Post a Comment